Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

NCT ID: NCT00906087

Last Updated: 2017-06-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-04
• Study Completion Date: 2012-07-18

Brief Summary

The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medication called Cosopt® (Merck & Co., Inc.).

Detailed Description

Glaucoma is an important public health issue, and identifying new markers to improve treatment outcomes is a high priority. Progress in Mendelian genetic approaches has led to identifying 15 genes and 31 loci (http://www.ncbi.nlm.nih.gov/); however, since these monogenic forms of glaucoma are uncommon, other approaches are needed to identify genetic markers that contribute to common risk factors, such as elevated eye pressure, eye pressure fluctuation, and drug response variation.

It is well known that eye pressure varies over a 24-hour period,1-6 but the mechanisms that regulate this eye pressure rhythm are not yet fully known. Drance reported that 84% of normal eyes (N=320 eyes) had eye pressure fluctuations of less than 5 mmHg in contrast to only 6% of untreated glaucomatous eyes (N=138).7 Drance clearly recognized that eye pressure factors were more variable in eyes with glaucoma. Attention to this eye pressure fluctuation during glaucoma treatment is important because fluctuation leads to progression. The variation in eye pressure drug response profiles measured at selected times over a 24-hour period is related to the mechanism of action of these drugs, endogenous circadian rhythms, and glaucoma. The molecular and genetic tools are now available to identify potential genetic markers for these variable traits.

Advancing clinical research to the "translational" level is an important step to integrate our ever increasing knowledge base in genomics and proteinomics with clinical trials and clinical studies. Given the infrastructure at the University of Michigan with the strength in both glaucoma genetics and our resources in the clinic, it is possible to test for relationships between glaucoma genes and eye pressure. Although it is known that myocilin (MYOC) mutations cause the phenotype of high pressure open-angle glaucoma, the effect of these MYOC mutations in "pre-symptomatic" subjects and patients with early open-angle glaucoma on eye pressure variation is not known.

Conditions

Glaucoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Cosopt

Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.

Group Type: OTHER

Cosopt (combination eyedrop of dorzolamide and timolol)

Intervention Type: DRUG

One drop in each eye every twelve hours for six weeks

Interventions

Cosopt (combination eyedrop of dorzolamide and timolol)

One drop in each eye every twelve hours for six weeks

Intervention Type: DRUG

Other Intervention Names

Cosopt

Eligibility Criteria

Inclusion Criteria

• Early OAG, as determined by a comprehensive ophthalmic examination
• Greater than or equal to 18 years of age
• Either gender
• Any race
• Both eyes meet eligibility criteria
• Cup to disc ratio less than 0.8 determined by fundoscopy and confirmed by disc photos
• Visual field parameters in the study eye: Pattern Standard Deviation (PSD) greater than 1.0 dB but less than 6.0 dB
• Ability to cooperate for an outpatient study involving at least five visits over a four month study period
• Ability to comply with Cosopt treatment regimen

Exclusion Criteria

• Less than or equal to 18 years old
• Refusal to be genotyped or sign Informed Consent for Protocol 1991-144
• Pregnant or lactating women
• Medical conditions of severe pulmonary compromise with asthma or emphysema or cardiac contraindications to beta-blockers
• Ocular disease of chronic angle-closure glaucoma, iridocorneal endothelial disease, posterior polymorphous corneal dystrophy, epithelial downgrowth, uveitic glaucoma, or neovascular glaucoma
• Ocular surgery for glaucoma, including trabeculectomy, other glaucoma filtration surgery, glaucoma drainage implant, or laser cyclophotocoagulation
• Current use of systemic steroids or chemotherapeutic agents that non-selectively inhibit dividing cells
• Proliferative diabetic retinopathy, history of panretinal photocoagulation treatment, diabetic macular edema, or history of macular grid laser treatment
• History of changing treatment involving the use oral beta-blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, or oral alpha 2-agonists in the prior two months or in the next month (i.e., must be on stable treatment with any of these drugs for at least two months)
• Patients taking erectile dysfunction drugs (i.e., Viagra, Cialis, Levitra)
• Contradictions:

• bronchial asthma or a history of bronchial asthma
• severe chronic obstructive pulmonary disease
• sinus bradycardia
• second or third degree atrioventricular block
• overt cardiac failure
• cardiogenic shock
• hypersensitivity to any component of Cosopt

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

University of Michigan

OTHER

Sponsor Role: lead

Responsible Party

Sayoko E. Moroi

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sayoko E Moroi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan Department of Ophthalmology and Visual Sciences

Locations

W.K. Kellogg Eye Center

Ann Arbor, Michigan, United States

Countries

United States

Other Identifiers

Merck IISP#31911

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

Merck IISP#31911

Identifier Type: -

Identifier Source: org_study_id